4Armitage J. The safety of statins in clinical practice[J]. Lancet, 2007, 370(9601) : 1781.
5Rrca M, Gaspardone A. A torvastatin efficacy in the primary and secondary prevention of cardiovascular events [ J ]. Drugs, 2007, 67(1) : S29.
6Liu B ,Cao HM, Li GY, et al. Effects of rosuvastatin versus atorvastatin on rho-associated coiled-coil containing protein kinase activity and endo- thelial function in patients with atherosclerosis [ J ]. J Int Med Res, 2011,39(6) :2314-2322.
7Bertram P, Loscalzo J, Monyak J, et al. Comparison of lipid-modifying ef- ficacy of rosuvastatin versus atorvastatinin patients with acute coronary syndrome ( from the LUNAR Study) [ J ]. Am J Cardiol, 2012,109 ( 9 ) : 1239-1246.
8Cheol WL, Kang SJ, Ahn JM', et al. Comparison of effects of atorvastatin (20 mg) versus msuvastatin( 10 nag) therapy on mild coronary athero- sclerotic plaques [ J ]. Am J Cardio1,2012,109 (12) : 1700 -1704.
9Greqory GS, Bolognese MA, Tremblay BP, et al. Efficacy and safety of rosuvastatin and atorvastatinin patients with hypercholesterolemia and a high-risk of coronary heart disease:a randomized, controlled trial [ J]. Am Heart J,2004,148( 1 ) :e4.
10Keijim S, Zhang B, Noda K. Randomized head-to-head comparison of pi- tavastatin, atorvastatin, and rosuvastatin for safety and efficacy ( quantity and quality of LDL) [J]. Circulation, 2011,75(6) :1493-1505.
